EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent progress on tyrosine kinase 2 JH2 inhibitors

Lidan Deng, Li Wan, Tingting Liao, Lin Wang, Jie Wang, Xianbo Wu, Jianyou Shi

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110434 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Lidan Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Sports Medicine and Health, Chengdu Sport University, Chengdu, Sichuan 610041, China. Hauptthemen laut MEDLINE: TYK2 Kinase, Janus Kinase Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Sichuan Province Science and Technology Support Program, National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family, which can regulate the signaling of multiple pro-inflammatory cytokines, including IL12, IL23 and type I interferon (IFNα/β), and its inhibitors can treat autoimmune diseases caused by the abnormal expression of IL12 and IL23. Interest in TYK2 JH2 inhibitors has increased as a result of safety concerns with JAK inhibitors. This overview introduces TYK2 JH2 inhibitors that are already on the market, including Deucravactinib (BMS-986165), as well as those currently in clinical trials, such as BMS-986202, NDI-034858, and ESK-001.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TYK2 KinaseJanus Kinase InhibitorsJanus KinasesSignal TransductionInterleukin-12

Stichwörter der Autor:innen

Autoimmune diseasesBMS-986202DeucravacitinibJH2 inhibitorTyrosine kinase 2 (TYK2)

Substanzen

TYK2 KinaseJanus KinasesJanus Kinase InhibitorsInterleukin-12

Autor:innen und Institutionen

  • School of Sports Medicine and Health, Chengdu Sport University, Chengdu, Sichuan 610041, China.
  • Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China.
  • College of Food and Bioengineering, Xihua University, Chengdu 610039, China.
  • Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550002, China.
  • School of Sports Medicine and Health, Chengdu Sport University, Chengdu, Sichuan 610041, China. Electronic address: cdutcmwu@163.com.
  • Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and…

Förderung

  • Sichuan Province Science and Technology Support Program
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Natural Science Foundation of Sichuan Province

Zitieren

APA

Deng, L., Wan, L., Liao, T., Wang, L., Wang, J., Wu, X., & Shi, J. (2023). Recent progress on tyrosine kinase 2 JH2 inhibitors. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110434

Vancouver

Deng L, Wan L, Liao T, Wang L, Wang J, Wu X, et al. Recent progress on tyrosine kinase 2 JH2 inhibitors. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110434

BibTeX
@article{Deng2023,
  author = {Deng, Lidan and Wan, Li and Liao, Tingting and Wang, Lin and Wang, Jie and Wu, Xianbo and Shi, Jianyou},
  title = {Recent progress on tyrosine kinase 2 JH2 inhibitors},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110434}
}
Kostenlos starten →